A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma
Satoshi Kobayashi(Kanagawa Cancer Center), Manabu Morimoto(Kanagawa Prefectural Hospital Organization), Satoshi Moriya(Yokohama City University Medical Center), Makoto Chuma(Yokohama City University Medical Center), Nobuhiro Hattori(St. Marianna University School of Medicine), Kazushi Numata(Yokohama City University Medical Center), Makoto Ueno(Kanagawa Prefectural Hospital Organization), Kotaro Matsunaga(St. Marianna University School of Medicine), Chika Kusano(Kitasato University), Kota Tsuruya(Tokai University), Shunji Hirose(Tokai University), Haruki Uojima(National Center for Global Health and Medicine), Tsunamasa Watanabe(St. Marianna University School of Medicine), Tatehiro Kagawa(Tokai University), Michihiro Suzuki(Tamagawa University), Taito Fukushima(Kanagawa Prefectural Hospital Organization), Motoko Suzuki(St. Marianna University School of Medicine), Hisashi Hidaka(Kitasato University)
Cited by 12
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells.
|Journal of Biological Chemistry|1990|1.5k
KN-62, 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazi ne, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II.
|Journal of Biological Chemistry|1990|625
N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, a calmodulin antagonist, inhibits cell proliferation.
|Proceedings of the National Academy of Sciences|1981|586